CLINICAL TRIALS PROFILE FOR THORAZINE
✉ Email this page to a colleague
All Clinical Trials for THORAZINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01231074 ↗ | Reducing Antipsychotic-Induced Weight Gain in Children With Metformin | Completed | Nationwide Children's Hospital | Phase 1 | 2010-02-01 | Recent but limited short term studies have shown that Metformin can slow down weight gain in obese children and in children with psychotropic-induced weight gain, two distinct pediatric populations that are at risk for obesity related co-morbid conditions. The purpose of this study is to conduct a long term prospective pilot cohort study to investigate the use of Metformin to prevent or decrease weight gain in two cohorts of children: 1) children with psychotropic induced weight gain on Metformin and 2) children with BMI above the 95th percentile on Metformin. Both study populations will be enrolled in a lifestyle weight management program |
| NCT03021486 ↗ | Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer | Active, not recruiting | National Cancer Institute (NCI) | Phase 2/Phase 3 | 2017-06-05 | This randomized phase II/III trial studies how well haloperidol with or without chlorpromazine works in treating delirium in patients with cancer that has spread to other parts of the body or has come back. Haloperidol and chlorpromazine may control the symptoms of delirium (loss of contact with reality) in patients with cancer. |
| NCT03021486 ↗ | Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer | Active, not recruiting | National Institute of Nursing Research (NINR) | Phase 2/Phase 3 | 2017-06-05 | This randomized phase II/III trial studies how well haloperidol with or without chlorpromazine works in treating delirium in patients with cancer that has spread to other parts of the body or has come back. Haloperidol and chlorpromazine may control the symptoms of delirium (loss of contact with reality) in patients with cancer. |
| NCT03021486 ↗ | Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer | Active, not recruiting | National Institutes of Health (NIH) | Phase 2/Phase 3 | 2017-06-05 | This randomized phase II/III trial studies how well haloperidol with or without chlorpromazine works in treating delirium in patients with cancer that has spread to other parts of the body or has come back. Haloperidol and chlorpromazine may control the symptoms of delirium (loss of contact with reality) in patients with cancer. |
| NCT03021486 ↗ | Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer | Active, not recruiting | M.D. Anderson Cancer Center | Phase 2/Phase 3 | 2017-06-05 | This randomized phase II/III trial studies how well haloperidol with or without chlorpromazine works in treating delirium in patients with cancer that has spread to other parts of the body or has come back. Haloperidol and chlorpromazine may control the symptoms of delirium (loss of contact with reality) in patients with cancer. |
| NCT04224441 ↗ | Repurposing Chlorpromazine in the Treatment of Glioblastoma | Recruiting | Carlo Besta Neurological Institute | Phase 2 | 2019-12-15 | This study evaluates the addition of chlorpromazine to the first-line therapeutic protocol, i.e. maximal well-tolerated surgical resection followed by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide, in newly diagnosed glioblastoma multiforme patients carrying a hypo-methylated O6-methylguanine-DNA-methyltransferase (MGMT) gene |
| NCT04224441 ↗ | Repurposing Chlorpromazine in the Treatment of Glioblastoma | Recruiting | Istituto Oncologico Veneto IRCCS | Phase 2 | 2019-12-15 | This study evaluates the addition of chlorpromazine to the first-line therapeutic protocol, i.e. maximal well-tolerated surgical resection followed by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide, in newly diagnosed glioblastoma multiforme patients carrying a hypo-methylated O6-methylguanine-DNA-methyltransferase (MGMT) gene |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for THORAZINE
Condition Name
| Condition Name for THORAZINE | |
| Intervention | Trials |
| Glioblastoma Multiforme | 2 |
| Locally Advanced Malignant Neoplasm | 1 |
| Malignant Neoplasms of Independent (Primary) Multiple Sites | 1 |
| Metastatic Malignant Neoplasm | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for THORAZINE
Trials by Country
Clinical Trial Progress for THORAZINE
Clinical Trial Phase
Clinical Trial Sponsors for THORAZINE
Sponsor Name
